# EDGAR Filing Document

**Accession Number:** 0001894525
**File Stem:** 0001213900-26-051125
**Filing Date:** 2026-5
**Character Count:** 147831
**Document Hash:** b0ddc80c2bac891e48b8bfaf4d0b029d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-051125.hdr.sgml**: 20260504

**ACCESSION NUMBER**: 0001213900-26-051125

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260424

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260504

**DATE AS OF CHANGE**: 20260504

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Apimeds Pharmaceuticals US, Inc.
- **CENTRAL INDEX KEY:** 0001894525
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 851099700
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42545
- **FILM NUMBER:** 26934535

**BUSINESS ADDRESS:**
- **STREET 1:** 100 MATAWAN RD
- **STREET 2:** SUITE 325
- **CITY:** MATAWAN
- **STATE:** NJ
- **ZIP:** 07747
- **BUSINESS PHONE:** 848-201-5010

**MAIL ADDRESS:**
- **STREET 1:** 100 MATAWAN RD
- **STREET 2:** SUITE 325
- **CITY:** MATAWAN
- **STATE:** NJ
- **ZIP:** 07747

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **April 24, 2026**

**Apimeds Pharmaceuticals US, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-42545** | **85-1099700** |
| (State or other jurisdiction <br> of incorporation) | (Commission File Number) | (I.R.S. Employer <br> Identification Number) |

---

---

| | |
|:---|:---|
| **100 Matawan Rd, Suite 325**<br> **Matawan, New Jersey** | **07747** |
| (Address of principal executive offices) | (Zip code) |

---

Registrant's telephone number, including area code: **(848) 201-5010**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.01 per share | APUS | NYSE American LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry into a Material Definitive Agreement.** 

On April 24, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the "**Company**"), MindWave Innovations Inc, a Delaware corporation and a wholly owned subsidiary of the Company ("**MindWave**"), and Lokahi Therapeutics, Inc., a Nevada corporation ("**Lokahi**" and, together with the Company and MindWave, the "**Company Parties**"), together with Erik Emerson ("**Emerson**"), individually and in his capacity as Bio Business Representative under the Agreement and Plan of Merger, dated December 1, 2025 (the "**Merger Agreement**"), entered into a Confidential Settlement and Mutual Release Agreement (the "**Settlement Agreement**"), with Inscobee Inc., a South Korean corporation ("**Inscobee**"), and Apimeds Inc., a South Korean corporation and wholly owned subsidiary of Inscobee ("**Apimeds Korea**", together with Inscobee, the "**Inscobee Parties**"). Concurrently with the Settlement Agreement, the Company Parties and the Inscobee Parties also entered into a Side Letter Agreement regarding the audits of the Company for the year ended December 31, 2025 (the "**Side Letter**"), which is incorporated into a forms part of the Settlement Agreement.

The Settlement Agreement resolves all outstanding disputes among the parties arising from the Merger Agreement and related transactions.

***Retention of Apitox Program by Lokahi; Working Capital Contribution***

 ****

Pursuant to the Settlement Agreement, Lokahi will retain all rights relating to the Apitox program, including all relevant intellectual property, regulatory materials, development data, manufacturing information, the Prevail CRO credit facility (having an aggregate value of approximately Two Million Two Hundred Thousand United States Dollars ($2,200,000)), and all other associated program assets. Lokahi will transfer to the Company (or its designee) Four Million United States Dollars ($4,000,000) (the "**Working Capital Contribution**") no later than five business days following the effective date of the Settlement Agreement. In addition, Lokahi will forgive all amounts previously advanced by Lokahi to the Company or any of its subsidiaries, including the $750,000 advance made on or about February 2, 2026, together with any associated interest, penalties, or equity rights. Following payment of the Working Capital Contribution, the Company will distribute 51% of the common stock of Lokahi as directed by Erik Emerson, the former chief executive officer of the Company, with the Company retaining the remaining 49%.

***Formation of Newco***

 ****

The Settlement Agreement provides for the formation of a new subsidiary of the Company ("**Newco**") within seven business days following the effective date. Newco will be a wholly owned subsidiary of the Company and will operate independently from Lokahi. Ten percent (10%) of the net financing proceeds from the Company's existing investor financing arrangement will be irrevocably allocated to Newco, with ninety percent (90%) allocated to MindWave. Newco is expected to be spun off from the Company within twelve months of the effective date of the Settlement Agreement, subject to a potential twelve-month extension upon approval by the Newco board of directors.

***Irrevocable Proxy***

 ****

In connection with the Settlement Agreement, the Inscobee Parties granted an irrevocable proxy to Dr. Vin Menon and Captain Sandeep Singh Yadav to vote all shares of common stock held by the Inscobee Parties with respect to the proposals described in its Information Statement on Schedule 14C, originally filed with the SEC on February 27, 2026, and first mailed to the Company's stockholders on March 5, 2026 (the "**Information Statement**"). The proxy is coupled with an interest and shall remain irrevocable until the later of (x) 30 days following receipt of NYSE approval of the listing application, (y) completion of the Preferred Stock Conversion and Note Approval, (z) the date on which NYSE provides a final denial of the listing application, or (aa) July 30, 2026.

***Merger Unwind Conditions Side Letter***

Under the Side Letter, the transactions contemplated by the Merger Agreement are subject to remedies as the parties may mutually agree in writing, upon the occurrence of either of the following events: (i) the Company's failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission on or before April 30, 2026; or (ii) the consolidated audit report included in such Form 10-K receiving a qualified opinion from the Company's PCAOB-registered independent auditors.

Upon the occurrence of either triggering event, the parties are required to meet and confer within five business days to negotiate in good faith an appropriate remedy, which may include unwind of the Merger Agreement, adjustment of the consideration exchanged thereunder, or such other relief as the parties may agree in writing. No party is bound by any particular remedy unless and until reduced to a written agreement signed by all parties. If a triggering event occurs due to the act or omission of a party, that party's voting rights and decision-making authority with respect to resolution of the triggering event are automatically delegated by irrevocable proxy to the non-defaulting parties; Lokahi, which is not a stockholder of the Company, is expressly excluded from receiving any such delegated voting rights.

***Mutual Releases***

 ****

Each of the parties to the Settlement Agreement has agreed to mutual releases of all claims, actions, and causes of action arising from facts, acts, omissions, circumstances, events, or transactions occurring prior to the execution of the Settlement Agreement, subject to customary carve-outs for breaches of the Settlement Agreement, fraud, intentional misrepresentation, indemnification rights, and tax claims. The releases become effective upon payment of the Working Capital Contribution by Lokahi.

***Dismissal of Lawsuit***

Within five business days after the effective date of the Settlement Agreement, Emerson is required to file a stipulation of dismissal without prejudice of the action filed by him in the United States District Court for the Southern District of New York against the Inscobee Parties (the "**Lokahi Action**"). The dismissal of the Lokahi Action will automatically convert to a dismissal with prejudice on the one hundred eightieth (180th) day after the effective date of the Settlement Agreement, provided there has been no breach by the Inscobee Parties of the Settlement Agreement.

The foregoing summaries of the Settlement Agreement and the Side Letter do not purport to be complete descriptions and are qualified in their entirety by reference to the full text of the Settlement Agreement and the Side Letter, copies of which are filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K and are incorporated herein by reference.

***Forbearance Agreement***

Also on April 30, 2026, the Company entered into a Forbearance Agreement (the "**Forbearance Agreement**") with Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B (the "**Investor**"), which holds a senior convertible note in the aggregate original principal amount of $11,000,000 (the "**Existing Note**"), issued pursuant to a Securities Purchase Agreement, dated December 1, 2025 (the "**Securities Purchase Agreement**").

Pursuant to the Forbearance Agreement, the Investor has agreed to forbear from exercising any of its rights or remedies under the Existing Note with respect to certain existing events of default (collectively, the "**Existing Defaults**") during the period commencing on the date of the Forbearance Agreement through and including June 30, 2026 (or such later date as the Investor may elect in its sole discretion) (the "**Forbearance Period**"). The Existing Defaults include the Company's failure to file a registration statement by the filing deadline, failure to cause the registration statement to be declared effective by the effectiveness deadline, failure to obtain stockholder approval by the stockholder approval deadline, breaches of representations and warranties arising from the Majority Stockholder Dispute, and the occurrence of a material adverse effect.

The Forbearance Period will terminate upon the earliest to occur of: (x) the occurrence, or discovery by the Investor, of any event of default under the Existing Note other than the Existing Defaults, (y) any breach of any term or condition of the Forbearance Agreement or the Settlement Agreement, or (z) the Company's failure to timely satisfy any of the forbearance conditions set forth in the Forbearance Agreement (the "**Forbearance Conditions**").

The Forbearance Conditions include, among other things: (i) delivery of the Settlement Agreement to the Investor; (ii) execution and delivery of Amendment No. 1 to the Existing Note; (iii) filing of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 with the SEC on or prior to April 30, 2026; (iv) filing of the initial registration statement with the SEC on or prior to May 10, 2026, with effectiveness on or prior to June 30, 2026; (v) curing all deficiencies and regaining compliance with the NYSE's continued listing requirements, including obtaining NYSE approval, effecting a 1-for-10 reverse stock split, and resuming trading of the Common Stock on the principal market, in each case on or prior to June 30, 2026; and (vi) causing the members of the Company's board of directors to be appointed in accordance with the Settlement Agreement on or prior to June 30, 2026.

Upon timely satisfaction of all Forbearance Conditions, the Investor will waive the Existing Defaults. The limited waiver constitutes a one-time waiver and is limited to the matters expressly waived in the Forbearance Agreement.

In connection with the Forbearance Agreement, the Company, on behalf of itself and its successors, assigns, and affiliates, provided a full and unconditional release in favor of the Investor and certain related parties from any and all claims arising out of or related to the Transaction Documents and the transactions contemplated thereby on or prior to the date of the Forbearance Agreement.

The Forbearance Agreement also amends the defined term "Transaction Documents" in the Securities Purchase Agreement to include the Forbearance Agreement. Except as expressly provided in the Forbearance Agreement, each of the Transaction Documents remains in full force and effect.

The foregoing summary of the Forbearance Agreement does not purport to be a complete description and is qualified in its entirety by reference to the full text of the Forbearance Agreement, a copy of which is filed as Exhibit 10.3 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** 

As previously disclosed, on December 30, 2025 and March 20, 2026, certain stockholders of the Company, including the Inscobee Parties, purported to execute written consents of stockholders (the "**Stockholder Consents**") to, among other things, remove Elona Kogan, Jakap Koo, Carol O'Donnell, and Dr. Bennett Weintraub from the Company's board of directors and appoint replacement directors.

In connection with the Settlement Agreement, the parties have agreed that the Support Agreements and Voting Agreements previously entered into by the Inscobee Parties in connection with the Merger Agreement are valid and binding, that the Stockholder Consents are void, and that all actions taken pursuant to the Stockholder Consents, including the purported removal of directors and any actions taken by the purported replacement board, are void. Accordingly, the Company's board of directors continues to consist of Elona Kogan, Jakap Koo, Carol O'Donnell, and Dr. Bennett Weintraub.

Under the Settlement Agreement, the Inscobee Parties have agreed to secure the resignation or removal of Mr. Koo. Following Mr. Koo's resignation or removal, and during the period between the effective date of the Settlement Agreement and the filing of the Company's Annual Report on Form 10-K (the "**Interim Period**"), the Company's board will consist solely of Ms. Kogan, Ms. O'Donnell and Dr. Weintraub. Following the Interim Period, unless the Company is advised that doing so would adversely affect the NYSE listing application, each of Ms. Kogan, Ms. O'Donnell and Dr. Weintraub will resign and the Company's board is expected to transition to three new independent directors in accordance with NYSE rules. Such directors will be appointed by the Inscobee Parties, subject to the reasonable approval of Dr. Vin Menon if permitted by the NYSE, and may not be affiliated with, connected to, or otherwise tainted by the Inscobee Parties. No member of the Company's board may be removed during this period without the written consent of Dr. Vin Menon and the Inscobee Parties.

Dr. Vin Menon continues to serve as Chief Executive Officer of the Company.

**Item 8.01. Other Events.** 

As previously disclosed, the Company filed the Information Statement providing for the following proposals (collectively, the "**Proposals**"): (i) the issuance of shares of the Company's common stock upon conversion of the Series A Convertible Preferred Stock, (ii) the issuance of shares of the Company's common stock upon conversion of convertible notes issued pursuant to the Securities Purchase Agreement entered into by the Company and certain institutional investors on December 1, 2025, and amended on December 8, 2025, (iii) a 1-for-10 reverse stock split and a change in par value from $0.01 to $0.001, together with a corresponding amendment to the Company's Amended and Restated Certificate of Incorporation, (iv) an amendment to the Company's 2024 Equity Incentive Plan to increase the number of shares issuable thereunder to 2,096,679, and (v) the approval and adoption of the Company's 2025 Equity Incentive Plan.

Under the Settlement Agreement, the parties have agreed that all Proposals set forth in the Information Statement shall proceed and become effective following the lifting of the current trading halt by NYSE American and approval of the Company's listing application. The Inscobee Parties have agreed to fully cooperate with the Company to facilitate the effectiveness of the Proposals, including providing any information, consents, or documents reasonably requested, and have agreed not to take any action, directly or indirectly, that would reasonably be expected to delay, impair, or prevent the effectiveness of the Proposals. Specifically, the Inscobee Parties have agreed to cooperate in good faith with the Company and to take all actions reasonably requested in connection with obtaining approval of the listing application in order to effect the actions described in each of the Proposals.

The Company does not intend to effect the actions described in the Proposals, other than the reverse stock split, unless and until NYSE American has approved the Company's listing application.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Confidential Settlement and Mutual Release Agreement, dated April 24, 2026, by and among Apimeds Pharmaceuticals US, Inc., MindWave Innovations Inc, Erik Emerson, Lokahi Therapeutics, Inc., Inscobee Inc., and Apimeds Inc.](ea028839301ex10-1.htm) |
| 10.2 | [Side Letter Agreement, dated April 24, 2026, by and among Apimeds Pharmaceuticals US, Inc., MindWave Innovations Inc, Erik Emerson, Lokahi Therapeutics, Inc., Inscobee Inc., and Apimeds Inc.](ea028839301ex10-2.htm) |
| 10.3 | [Forbearance Agreement, dated April 30, 2026, by and between Apimeds Pharmaceuticals US, Inc. and Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B.](ea028839301ex10-3.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Apimeds Pharmaceuticals US, Inc. | Apimeds Pharmaceuticals US, Inc. |
| Date: May 3, 2026 | By: | */s/ Dr. Vin Menon* |
|  | Name: | Dr. Vin Menon |
|  | Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**<u>CONFIDENTIAL SETTLEMENT AND MUTUAL RELEASE AGREEMENT</u>**

THIS CONFIDENTIAL SETTLEMENT AND MUTUAL RELEASE (this "***Agreement***"), between Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the "***Company***"), MindWave Innovations Inc, a Delaware corporation and a wholly owned subsidiary of the Company ("***MindWave***"), Erik Emerson, individually and as Bio Business Representative under the Merger Agreement referenced below ("***Emerson***"), Lokahi Therapeutics, Inc., a Nevada corporation ("***Lokahi***," together with the Company and MindWave, the "***Company Parties***" and for purposes of Section 14 and Section 15, Emerson and Lokahai shall be the "***Lokahai Parties"***), Inscobee Inc., a South Korean corporation ("***Inscobee***"), and Apimeds Inc., a South Korean corporation and wholly owned subsidiary of Inscobee ("***Apimeds Korea***" together with Inscobee, the "***Inscobee Parties***") is dated April 24, 2026 (the "***Effective Date***").

**BACKGROUND**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. The Company, MindWave, Lokahi, Emerson and the other signatories thereto entered an Agreement and Plan
of Merger dated December 1, 2025 (the "  ***Merger Agreement***") under which, among other things, the pre-closing stockholders
of MindWave received preferred stock of the Company in exchange for their ownership interest in MindWave.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. Concurrently with the Merger Agreement, the Company, MindWave, and Lokahi entered into that certain amended
and restated side letter agreement dated December 1, 2025 (the "  ***Side Letter***") regarding, among other things,
the allocation of certain funds from the Investor to Lokahi and MindWave.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. In connection with the Merger Agreement, the Company filed an information statement on Form 14C (the "  ***Information Statement*** "), to (i) issue shares of the Company's common stock, par value $0.01 per share upon the conversion of the
Series A convertible preferred stock of the pre-closing holders of MindWave into Company common stock (the "  ***Preferred Stock Conversion***") upon the terms of the Merger Agreement, (ii) issue shares of Company common stock upon the conversion of the
convertible notes issued by the Company to the Investor pursuant to that certain Securities Purchase Agreement, entered into by the Company
and certain institutional investors on December 1, 2025, and amended by that certain Amendment No. 1 to Securities Purchase Agreement
on December 8, 2025, in an amount that may be equal to 20% or more of the Company's pre-transaction outstanding common stock, pursuant
to NYSE Section 312.03(c) (the "  ***Note Approval*** "), (iii) effect a 1-for-10 reverse stock split (the "  ***Reverse Stock Split***") of the shares of the Company's common stock and change the par value per share of the Company's
common stock from $0.01 to $0.001 (the "  ***Change in Par Value*** "), and a corresponding amendment to the Company's
Amended and Restated Certificate of Incorporation to authorize the Company's board of directors to effect the Reverse Stock Split
and the Change in Par Value, (iv) amend the Company's 2024 Equity Incentive Plan to increase the number of shares of Company common
stock issuable under the plan to 2,096,679 (the "  ***2024 Plan Share Increase*** "), and (v) approve and adopt the Company's
2025 Equity Incentive Plan (the "  ***2025 Plan Approval*** "). The Preferred Stock Conversion, the Note Approval, the
Reverse Stock Split and the Change in Par Value, the 2024 Plan Share Increase, and the 2025 Plan Approval shall be referred to as the
"  ***Proposals*** ". For the avoidance of doubt, the time following the Preferred Stock Conversion shall be referred
to as "  ***Post-Closing*** *.* "

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. As a result of the transactions contemplated by the Merger Agreement, including the Preferred Stock Conversion
and the Note Approval, following the effectiveness of the Preferred Stock Conversion and the Note Approval, a change in control of the
Company will occur within the meaning of the NYSE American Company Guide. Accordingly, the Company was required to submit a new listing
application to NYSE American before the effectiveness of the Preferred Stock Conversion and the Note Approval (the "  ***Listing Application*** "). The Company does not intend to affect the Preferred Stock Conversion and the Note Approval unless and until
NYSE American has approved the Listing Application.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E. Since the signing of the Merger Agreement, a dispute has arisen among the parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;F. Because the Inscobee Parties previously entered into the Support Agreements (as defined below), the Company
Parties dispute the effectiveness of the Stockholder Consents (as defined below) and declared them void and, therefore, making any such
actions that flow from the Stockholder Consents void; however, the Inscobee Parties dispute the validity of the Support Agreements and
believe that the Stockholder Consents are valid as were any actions taken pursuant to such Stockholder Consents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;G. The parties desire to settle and resolve all outstanding issues between them without litigation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;H. In connection with the Investor Financing (as defined below), the parties also desire to waive certain
covenants in the Merger Agreement and Side Letter as described below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I. It is agreed that the Company shall distribute the shares of Lokahai as provided herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;J. The parties also wish to clarify the Company's board of directors and management by causing the
Inscobee Parties to amend or replace their beneficial ownership reports on Section 13D filing and cooperate with the Company in preparing
a press release that the Company shall release regarding the resolution of the dispute.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;K. A new subsidiary/SPV of the Company ("  ***Newco*** *")* will be formed and run
by the Co- CEO.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;L. Newco shall be spun off within 12 months of the Effective Date as agreed between the Board of Directors
and the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;M. Notwithstanding the foregoing, such period may be extended once, for an additional period not to exceed
twelve (12) months, upon approval by the board of directors of Newco.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N. In consideration of the foregoing and the mutual covenants and agreements contained in this Agreement,
the receipt and sufficiency of which is acknowledged, the parties agree as follows:

**AGREEMENT**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1. Conditions Precedent**. The conditions of each party to consummate the transactions contemplated by this Agreement, will be subject to the satisfaction or written waiver (where permissible) of the following conditions on or before the Effective Date. All deliveries and actions described in this Section 1 shall be deemed to occur simultaneously; no delivery shall be effective until all other concurrent deliveries are completed on or before the Effective Date. All deliveries and actions described in this Section 1 shall be deemed to occur simultaneously; no delivery shall be effective until all other concurrent deliveries are completed:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. *Investor Letter*. On or before the Effective Date, the Company shall receive a letter from the Investor (as such term is defined in the Side Letter) confirming temporary forbearance and conditional withdrawal of the existing default demand, subject to the following: (i) execution and ongoing compliance with this Agreement, (ii) timely filing of the Company's Form 10-K on or before April 30, 2026, (iii) remediation of all NYSE related matters no later than June 30, 2026 including but not limited to approval of the NYSE Listing Application, Note Approval, Preferred Stock Conversion, unhalt of the Company's common stock and maintenance of listing until June 30, 2026, (v) no additional Events of Default (as defined in the Notes) have occurred. Any waiver of existing defaults shall be expressly conditioned upon, and shall only become effective upon, the full and timely satisfaction of all such conditions and the absence of any additional Events of Default as of June 30, 2026, as confirmed in writing by the Investor. Until such time, all defaults shall remain continuing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. *Irrevocable Proxy*. Subject to the satisfaction of Section 1.a, the Inscobee Parties shall deliver to the Company duly executed copies of a new Irrevocable Proxy (as defined below). The Inscobee Parties shall cause the Reporting Persons to execute the Irrevocable Proxy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. *Rescission of the Stockholder Consents*. Subject to the satisfaction of Section 1.a, The Inscobee Parties shall cause all parties to the Stockholder Consents to enter into a new stockholder consent, in form and substance agreeable to Mindwave and the Company, that rescinds all actions taken in the Stockholder Consents, including the purported amendment to the bylaws of the Company, declares any actions taken by the purported Company board of directors appointed pursuant to the March Consent void, including any terminations of officers of the Company that were duly appointed as of March 19, 2026, and to avoid any further confusion regarding corporate governance, reappoints the prior Company's board of directors in place as of March 19, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. *Ratification of the Support Agreement and Voting Agreement .* The Inscobee Parties hereby confirm the terms and conditions of the Support Agreement and Voting Agreement and shall abide by the terms of the Support Agreement and Voting Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. *Agreement Approvals*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. Inscobee shall deliver to the Company evidence satisfactory to the Company and MindWave that the board of directors of Inscobee has authorized this Agreement and the transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Apimeds Korea shall deliver to the Company evidence satisfactory to the Company and MindWave that the board of directors of Apimeds Korea has authorized this Agreement and the transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. The Company shall deliver to Inscobee and Apimeds Korea evidence satisfactory to Inscobee and Apimeds Korea that the board of directors of directors of the Company has authorized this Agreement and the transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. The Company shall cause to be delivered to Inscobee and Apimeds Korea evidence satisfactory to Inscobee and Apimeds Korea that the sole stockholder of MindWave and Lokahi has authorized this Agreement and the transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;v. Interdependence of Deliveries. Notwithstanding anything to the contrary, the Inscobee Parties shall have no obligation to deliver the items set forth in Sections 1(b) and 1(c) unless and until the Company has delivered the items set forth in Sections 1(a) 1(d)(iii), and 1(d)(iv) to Inscobee in a form reasonably satisfactory to Inscobee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2. Investor Financing**. The Company previously entered into a financing arrangement with the Investor (the "Investor Financing"). The Inscobee Parties and the Company Parties agree to reasonably cooperate with MindWave in connection with the Investor Financing, including, but not limited to, avoiding any action or failing to take any action that would cause a breach under the Investor Financing agreements. Notwithstanding the foregoing, for the avoidance of doubt, the Inscobee Parties shall have no obligation to provide, source, guarantee, or otherwise participate in any portion of the Investor Financing, and shall have no liability for any failure to obtain or maintain such financing, except as provided in Section 1 d or for their failure to cooperate as provided in this paragraph.

All costs, fees, and expenses related to the formation of Newco shall be borne solely by the Company. The initial capitalization shall come from the Working Capital Contribution (as defined below). All funds derived from the Investor Financing, net of any investment banking fees, commissions, and other transaction-related costs (the "Net Financing Proceeds"), shall be allocated and disbursed by the Company. The Company shall disburse the Net Financing Proceeds as follows: (i) ninety percent (90%) of the Net Financing Proceeds shall be irrevocably allocated to, and disbursed directly into the accounts of, MindWave; and (ii) ten percent (10%) of the Net Financing Proceeds shall be irrevocably allocated to, and disbursed directly into the accounts of, Newco. The foregoing allocation shall apply to all Net Financing Proceeds received by the Company during the twelve (12) month period following the Effective Date (the "Allocation Period") and shall be binding on the Company for the duration of the Allocation Period. The co-CEO shall not have any access to the deposit accounts established under the Investor Financing, and shall have no ability to draw upon the Investor Financing without the MindWave chief executive officer.

The portion of such funds allocated to MindWave shall be under the sole control of the MindWave chief executive officer in his sole discretion; provided, however, that the portion allocated to Newco shall be utilized solely for its designated operational purposes and shall not be subject to the sole discretion of the MindWave chief executive officer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3. Formation and Governance of Newco**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. *Formation of Newco .* Within 7 business days following the Effective Date, the Company shall form Newco as a corporation in a U.S. jurisdiction and with a name, in each case chosen the Company, which shall operate independently from Lokahi. Newco shall be a wholly-owned subsidiary of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. *Governance*. The business and affairs of Newco shall be managed and directed independently by its own board of directors and officers duly appointed in accordance with Newco's governing documents. One member of the board of directors of Newco shall be the Company's CEO.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. Newco shall be permitted to raise equity securities, other than equity securities convertible into shares of the Company, at such prices and amounts as determined by its board of directors. Any such equity securities shall dilute the interests of the Company in Newco.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Newco shall not be permitted to raise any debt securities or incur any liabilities in excess of USD $25,000 or issue equity securities convertible into shares of the Company without the prior written consent of the Company's CEO and the Investor. No debt issued by Newco may be guaranteed by the Company and must be non-recourse to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. Newco shall make available all of its books and records in a timely manner so that the Company can comply with its SEC reporting obligations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. Newco shall pay within one business day of receipt of the Working Capital Contribution $750,000 to Duane Morris LLP and up to $750,000 to the Insocbee Parties' legal team.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;v. Newco shall be spun-off from the Company not later than twelve (12) months from the Effective Date on such terms as shall be agreed between the Company and the NewCo board of directors. Notwithstanding the foregoing, such period may be extended once, for an additional period not to exceed twelve (12) months, upon approval by the board of directors of Newco.

**4. Contribution by, and assignment to, Lokahi**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. *Payment by Lokahi*. Lokahi hereby irrevocably agrees and unconditionally undertakes to transfer to the Company, or, if designated in writing by the Company prior to such transfer, directly to Newco, an amount equal to Four Million United States Dollars (USD $4,000,000) (the "***Working Capital Contribution***"), no later than five (5) business days following the Effective Date. The obligation of Lokahi to make the Working Capital Contribution shall be absolute and unconditional, shall not be subject to any condition precedent, and shall not be reduced, withheld, or delayed by reason of any set-off, counterclaim, deduction, defense, or other right, whether arising under this Agreement or otherwise. Any failure by Lokahi to timely fund the Working Capital Contribution shall constitute a material breach of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. *Transfer of CRO Credit Facility*. To support continued development of the Apitox program, the Company shall assign to Lokahi the Prevail CRO credit facility having an aggregate value of approximately Two Million Two Hundred Thousand United States Dollars (USD $2,200,000) (the "***Prevail Credit Facility***").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. *Retention of Apitox Program Assets*. Lokahi shall retain all rights relating to the Apitox program, including, without limitation: (a) all relevant intellectual property, (b) all regulatory materials, (c) all development data, (d) all manufacturing information, and (e) all other associated program assets to the extent such rights are currently licensed to the Company (collectively, the "**Apitox Program Assets**"). The Company shall assign the rights under such license agreement to Lokahi and the Inscobee Parties shall consent to the assignment of such license.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. *Forgiveness of Debt*. Lokahi shall forgive, release, and discharge all amounts advanced by Lokahi to the Company or any of its subsidiaries, including, for the avoidance of doubt, the $750,000 advanced on or about February 2, 2026, together with any interest, penalties or equity that may be due Lokahai.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. *Spinoff .* Within five (5) business days following payment of the Working Capital Contribution, the Company shall distribute 51% of the common stock of Lokahi as directed by Emerson. The remaining 49% shall be held by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. *No Further Action.* From and after the Effective Date, no Inscobee Party or Company Party shall, directly or indirectly, and each shall cause its affiliates not to, in respect of Lokahi: (i) deliver, solicit, or support any stockholder consent or proposal; (ii) deliver or support any demand under NRS § 78.257 or any analogous books-and-records or information statute; (iii) disparage any Lokahi Party; or (iv) finance, assist, or coordinate with any third party in any of the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. *Lokahi Board and Management*. Lokahi's board composition and its officer, employee, consultant, and advisory appointments shall be determined solely by Lokahi. No Inscobee Party, or any affiliate, nominee, or current or former employee of any of the foregoing shall serve in any such capacity at any time. Erik Emerson continues as Lokahi's CEO and President, and no party other than Lokahi may remove, suspend, or limit his authority.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5. Merger Agreement Waiver by Lokahi, Emerson and the Bio Business Representative**. For the avoidance of doubt and in connection with the Investor Financing, Lokahi, Emerson and the Bio Business Representative each irrevocably waives the following covenants in the Merger Agreement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. The rights of the Bio Business Representative or Emerson to receive regular updates from the Company's management and Lokahi's management, including quarterly reports on operations, financing allocations, and material development in accordance with Section 7.08(h) of the Merger Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. In accordance with Section 7.08(h) of the Merger Agreement, any rights of the Bio Business Representative or Emerson to seek specific performance, injunctive relief, or other equitable remedies, and neither shall have standing to bring legal action in any court of competent jurisdiction to enforce the obligations under the Merger Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. All obligations from the Company to Lokahi under Section 7.08(i) of the Merger Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Any and all other rights under the Merger Agreement directly or indirectly attributed or belonging to the Bio Business Representative or any rights to the Investor Financing under the Merger Agreement or the Side Letter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6. Side Letter Waiver by Lokahi**. For the avoidance of doubt and in connection with the Investor Financing, Lokahi irrevocably waives the following covenants in the Side Letter:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. *Allocation of the Closing Funds*. Lokahi waives any rights it had to any funds allocated to, received by, or raised by the Company in connection with Section 1 of the Side Letter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. *Allocation of the Registration Funds*. Lokahi waives any rights it had to any funds allocated to, received by, or raised by the Company in connection with Section 2 of the Side Letter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. *Allocation of the PIPE Investor's Funds*. Lokahi waives any rights it had to any funds received by the Company in connection with Section 3 of the Side Letter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. *Future Financing*. Lokahi waives any rights it had to any funds raised by the Company in connection with Section 4 of the Side Letter and any other previously agreed fund agreement or understanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. *Diligence Fee*. Lokahi waives any rights it had to be repaid from the Closing Funds (as such term is defined in the Side Letter) for advancing $50,000 diligence and expenses in accordance with Section 6 of the Side Letter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. *General Waiver*. Any and all other rights under the Side Letter directly or indirectly attributed or belonging to the Bio Business Representative or any rights to the Investor Financing under the Side Letter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7. Irrevocable Proxy**. Pursuant to the irrevocable proxy substantially in the form attached as <u>Exhibit A</u> (the "***Irrevocable Proxy***"), the Inscobee Parties shall appoint Dr. Vin Menon ("***Menon***") and Captain Sandeep Singh Yadav ("**Yadav**"), with full power of substitution, as the proxies of the Inscobee Parties with respect to the matters set forth in the Irrevocable Proxy and will authorize either of them to represent and to vote the stock held by the Inscobee Parties as of the Effective Date for such matters. The proxy granted by the Irrevocable Proxy will be given in consideration of the agreements and covenants of the Company in connection with the transactions contemplated by this Agreement and, as such, is coupled with an interest and shall be irrevocable until the later of (x) 30 days following the receipt of NYSE approval of the Listing Application, (y) the completion of the Preferred Stock Conversion and Note Approval following such NYSE approval or (z) the date on which NYSE provides a final, non-appealable denial or rejection of the application for such approval; or (aa) July 30, 2026 (the "**Outside Date**") (each of (x), (y), (z) and (aa), Listing Application (the "**Sunset Date**").

Upon the occurrence of the Sunset Date, the Irrevocable Proxy shall automatically terminate and be of no further force or effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8. Post-Signing Covenants**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. *Listing Requirements*. The Inscobee Parties agree to cooperate in good faith with the Company and to take all actions reasonably requested by the Company in connection with obtaining approval of the Listing Application in order to effect the Preferred Stock Conversion and the Note Approval. Such cooperation shall include, without limitation, providing requested information, executing required documentation, and refraining from taking any action that would reasonably be expected to delay, impair, or adversely affect the Company's ability to obtain approval of the Listing Application, Preferred Stoc Conversion or Note Approval. However, such cooperation is strictly contingent upon the following: (i) All costs (including reasonable legal fees solely in connection with the settlement of this Agreement) shall be discharged by Newco from the Working Capital Contribution within 5 business days of request; (ii) The Company must be in compliance with the terms that are applicable to Company while discharging its obligations (and to the extent commercially reasonable and technically feasible) with all obligations under this Agreement; (iii) Cooperation shall not impose any additional financial liability, except as provided above, or violate fiduciary duties of the Inscobee Parties; and (iv) The Company shall provide weekly status updates and copies of all regulatory correspondence to the Inscobee Parties until the Preferred Stock Conversion and Note Approval is complete. If the settlement is not completed successfully, each party will cover their own subsequent cost including legal cost<u>.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. *Company and Inscobee Press Release*. The Inscobee Parties agree that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. <u>Schedule 13D Withdrawal</u>. The Inscobee Parties shall amend any and all beneficial ownership reports on Schedule 13D previously filed by the Inscobee Parties with the U.S. Securities and Exchange Commission promptly following the Effective Date but, in any event, no later than four (4) business days of the Effective Date. The Inscobee Parties shall amend the beneficial ownership reports on Schedule 13D required to be filed with the U.S. Securities and Exchange Commission in form and substance as agreed upon by the Inscobee Parties and Menon. In such amended Schedule 13D, the Reporting Persons shall confirm their commitment to the closing of the transactions contemplated by the Merger Agreement and their votes described below to reappoint the Board of Directors and officers of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. <u>Press Release</u>. The Inscobee Parties, Lokahai and the Company shall cooperate in good faith to prepare and issue a mutually agreed joint press release announcing this Agreement and the settlement of the matters contemplated by this Agreement no later than five (5<u>)</u> business days of the Effective Date. No press release or public statement shall characterize any Company or Lokahi contribution, transfer, waiver, or release as distressed, coerced, compelled, or the product of financial necessity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. *Information Statement*. The Inscobee Parties agree to fully cooperate with, and take all actions reasonably requested by, the Company to facilitate the effectiveness of the Proposals, including providing any information, consents, or documents reasonably requested in connection with the effectiveness of the Proposals. The Inscobee Parties further agree that they shall not take any action, directly or indirectly, that would reasonably be expected to delay, impair, or prevent the effectiveness of the Proposals, including, but not limited to taking any action to impede, revoke, or otherwise attempting to impede or revoke the Irrevocable Proxy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. *Annual Report on Form 10-K*. Inscobee Parties agree to fully cooperate with, and take all actions reasonably requested by, the Company in connection with the completion of the Company's Annual Report on Form 10-K (the "***10-K***"). The Inscobee Parties further agree that they shall not take any action, directly or indirectly, that would reasonably be expected to delay, impair, or prevent the filing of the 10-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. *Regulatory Approvals*. Inscobee Parties agree to fully cooperate with, and take all actions reasonably requested by, the Company in connection with any approvals required to be obtained from any Governmental Authority in to consummate the transactions contemplated by this Agreement. For purposes of this Agreement, "***Governmental Authority***" shall mean means any federal, state, local, foreign or other governmental, quasi-governmental or administrative body, instrumentality, department or agency or any court, tribunal, administrative hearing body, arbitration panel, commission, or other similar dispute-resolving panel or body.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9. Void Actions**. On December 30, 2025, the Inscobee Parties purported to pass a written consent of a majority of the stockholders of the Company ("***December Consent***") to remove Emerson as a director of the Company. Also, on March 20, 2026, the Inscobee Parties in connection with certain other stockholders of the Company purported to pass a written consent of the stockholders of the Company ("***March Consent***" together with the December Consent, collectively, the "***Stockholder Consents***") to, among other things, (i) adopt the second amendment to the amended and restated bylaw of the Company in connection with changes to the Company's board of directors, (ii) appoint Youngjik Cho, Minguk Ji, and Junyoung Yu as directors of the Company's board of directors, and (iii) remove Elona Kogan, Jakap Koo, Carol O'Donnell, and Dr. Bennett Weintraub from the Company's board of directors. The Inscobee Parties previously entered into a support agreement (the "***Support Agreements***") and voting agreements (the "***Voting Agreements***") in connection with the Merger Agreement that, if validly entered into, prohibited them from voting in favor of changing the Company's board of directors while the Support Agreements or Voting Agreements were in place or taking any other action that would prevent the closing of the transactions contemplated by the Merger Agreement. In connection with this Agreement, the parties agree that the Company Support Agreements and Voting Agreements are valid and binding agreements of the Inscobee Parties and, thus, should treat the Stockholder Consents as void. Therefore, the parties recognize that the ownership held by the remaining stockholders, excluding the Inscobee Parties, signatory to the Stockholder Consents is insufficient to take such stockholder actions, and are therefore, void. All such actions deriving from the Stockholder Consents, including the actions of the purported board in terminating the executives of the Company are void.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10. The Boards**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. *Company Board*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. <u>Interim Period</u>. During the period of time between the Effective Date and the filing of the Form 10-K, the Company's Board of Directors shall consist solely of Elona Kagan, Carol O'Donnell and Dr. Bennett Weintraub (such time period referred to as the "***Interim Period***"). The Inscobee Parties shall either secure the resignation of Jakap Koo, or cause his removal. At the end of the Interim Period, unless the Company has been advised that the replacement of the Board of Directors would adversely affect the Listing Application, Elona Kogan, Carol O'Donnell, and Dr. Bennett Weintraub shall each resign as directors of the Company. The Company's board of directors shall, from such date until the completion of the Preferred Stock Conversion, consist solely of three (3) new independent directors in accordance with NYSE rules, who are appointed by the Inscobee Parties, but subject to the reasonable approval of Menon in accordance with any NYSE limitations; provided, that no such person shall be affiliated with, connected to, or otherwise tainted by the Inscobee Parties. No members of the Company's board of directors shall be removed without the written consent of Menon and the Inscobee Parties until the completion of the Preferred Stock Conversion. Menon shall serve as Chief Executive Officer of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. <u>Post-Effective Date</u>. The parties will take all necessary action, including, regardless of whether required, causing the directors of Company that had been appointed pursuant to the Stockholder Consents to resign, so that Post-Closing, the Company's board of directors shall consist of three (3) members as described above. Following the Preferred Stock Conversion, the Board shall consist of seven (7) members. Four (4) members of the Company's board of directors shall be nominated by Mindwave and required to qualify as an independent director under the relevant listing rules, two (2) members of the Company's board shall be nominated by Menon, one of whom shall be Menon and one (1) member shall be the Co-CEO. The parties will take all reasonable steps to ensure that the Company's board complies with all requirements of the applicable listing exchange rules. No members of the Company's Post-Closing board of directors shall be removed without the written consent of Menon.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. *MindWave Board*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. <u>Interim Period</u>. During the Interim Period, the MindWave board of directors shall continue to be Menon. The MindWave board of directors shall have sole and complete authority and control over the business and affairs of MindWave and its wholly owned subsidiaries including but not limited to (a) to manage and direct all operations of MindWave, (b) control and access to all bank accounts and other financial accounts of MindWave, (c) the authority to approve or disapprove all expenditures, obligations, and other commitments of funds, (d) authorize any hiring, termination, or compensation decisions with respect to personnel, and (e) approve the receipt, use, and disbursement of any and all funds or other assets of MindWave. No members of the Lokahi board of directors shall be removed without the written consent of Menon.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. <u>Post-Closing</u>. The parties will take all necessary action, so that Post-Closing, MindWave's board of directors shall consist of five (5) members. Menon shall remain on the MindWave board of directors and serve as Executive Chairman. Menon shall have the right to designate three (3) additional members of MindWave board of directors. The MindWave Board shall retain sole and complete authority and control over the business and affairs of MindWave and its wholly owned subsidiaries including but not limited to (a) to manage and direct all operations of MindWave, (b) control and access to all bank accounts and other financial accounts of MindWave, (c) the authority to approve or disapprove all expenditures, obligations, and other commitments of funds, (d) authorize any hiring, termination, or compensation decisions with respect to personnel, and (e) approve the receipt, use, and disbursement of any and all funds or other assets of MindWave.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. <u>Limits on Powers of the Company Over MindWave</u>. The Company shall not without written consent of Menon and the MindWave board of directors:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Amend or propose to amend MindWave's certificate of incorporation, bylaws, or similar organizational documents;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. split, combine, reclassify, or otherwise alter the MindWave's outstanding capital stock, equity interests, voting securities, or issue or authorize any securities in substitution thereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. issue, sell, pledge, dispose of, or encumber any shares of the MindWave's capital stock, securities convertible into such stock, or any options, warrants, calls, or rights to acquire shares of MindWave capital stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. sell, lease, license, transfer, mortgage, pledge, or otherwise dispose of or encumber any material assets or properties of MindWave;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. discontinue any material business lines of MindWave;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. enter into, amend, modify, terminate, or waive rights under any material contract, lease, or agreement of MindWave;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. dispose of, fail to maintain, or grant licenses to any intellectual property rights, or subject any assets to new liens or encumbrances of MindWave;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. engage in or become a party to any merger, consolidation, share exchange, business combination, recapitalization, or similar transaction involving MindWave;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. enter into any collective bargaining agreement, labor union contract, or similar agreement involving MindWave;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. commence, settle, or compromise any material litigation, claims, or legal proceedings, or waive/release material rights related to MindWave;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. reduce in force, layoff or make any material changes to any compensation or benefits plans of MindWave;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. make, change, or revoke any tax election of MindWave;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. settle or compromise any tax liability of MindWave;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. extend or waive any limitations periods for tax assessments of MindWave; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. fail to maintain in full force all material insurance policies covering MindWave.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11. Management Structures**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. *Company*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. <u>Resignation of the Purported Company Officers</u>. As of the Effective Date, the Inscobee Parties will cooperate with the Company to take such action as necessary to cause any of the individuals purporting to serve as an officer or director of the Company to resign or be terminated by the Company's Interim Period board of directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. <u>Company Chief Executive Officer</u>. Menon continues to be the chief executive officer of the Company. Subject to approval by the Company's board of directors as of the Effective Date, the parties agree that the Company shall take all necessary actions to appoint a co-chief executive officer of the Company, to be designated by the Inscobee Parties, within seven (7) days of the Effective Date. The co-chief executive officers shall cooperate to perform the duties of the chief executive officer in accordance with the Company's governing documents; provided that Menon shall have final authority over actions of the Company and Mindwave and the co-chief executive officer shall have final authority over Newco, except as provided herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. <u>Company Chief Financial Officer</u>. Until the filing of the Company's 10-K for the period ended December 31, 2025, Erick Frim shall continue to be the chief financial officer of the Company. Subject to approval by the Company's board of directors and following the filing of the 10-K, the parties agree that the Company shall take all necessary actions to appoint an individual designated by Menon and the co-chief executive officer as the chief financial officer of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. <u>Company</u> President. To the extent the office of president of the Company is not vacant as of the date of the Lokahai spinoff, the Company's board of directors shall take such action as necessary to remove any person appointed to such position. Emerson hereby waives any termination payments under the terms of his employment by the Company that may be due him as a result of the transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. *MindWave*. Unless otherwise determined by the MindWave board of directors or resignation of such officer, the chief executive officer of MindWave shall remain Menon. The CEO of MindWave shall have such powers as provided in the MindWave organizational documents and authorized by the MindWave board of directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12. Intentionally left blank**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**13. Intentionally left blank**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**14. Intentionally left blank**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**15. Confidentiality**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. *Restrictions on Disclosure of Information*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. Without limiting any rights or obligations under any other agreement between or among the parties and/or any of their respective affiliates relating to confidentiality, for a period of three (3) years following the Effective Date, each of the parties agrees that it shall not, and shall not permit any of its affiliates or representatives to, disclose any Confidential Information to any person, other than to such affiliates or representatives on a need-to-know basis in connection with the purpose for which the Confidential Information was originally disclosed. Such information shall no longer be deemed Confidential Information to the extent that it is or was (i) in the public domain other than by the breach of this Agreement or by breach of any other agreement between or among the parties and/or any of their respective affiliates, (ii) available to such party outside the context of the prior relationship on a nonconfidential basis before its disclosure by the other party, (iii) lawfully acquired outside the context of the prior relationship on a nonconfidential basis or independently developed by, or on behalf of, such party by persons who do not have access to, or descriptions of, any such Confidential Information, (iv) required to be disclosed by law, governmental order or the rules and regulations of the SEC, or (v) mutually agreed to by the parties. For purposes of this Agreement, "***Confidential Information***" shall mean with respect to any party, any and all records, books, contracts, instruments, computer data and other data concerning such party, its business or any of its affiliates that was obtained by another party any other records, books, contracts, instruments, computer data and other data obtained by, or furnished to, another party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Each of the parties shall maintain, and shall cause its respective affiliates to maintain, policies and procedures, and develop such further policies and procedures as shall from time to time become necessary or appropriate, to ensure compliance with this Section.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. *Legally Required Disclosure of Confidential Information*. If any of the parties to this Agreement or any of their respective affiliates or representatives become legally required to disclose any Confidential Information, such disclosing party shall promptly notify the party owning the Confidential Information (the "***Owning Party***") and shall use all commercially reasonable efforts to cooperate with the Owning Party so that the Owning Party may seek a protective order or other appropriate remedy and/or waive compliance with this section. All expenses reasonably incurred in seeking a protective order or other remedy shall be borne by the Owning Party. If such protective order or other remedy is not obtained, or if the Owning Party waives compliance with this section, the disclosing party or its affiliate or representative, as applicable, shall (a) disclose only that portion of the Confidential Information it is compelled by law to disclose, (b) use all commercially reasonable efforts to obtain reliable assurance requested by the Owning Party that confidential treatment will be accorded such Confidential Information, and (c) promptly provide the Owning Party with a copy of the Confidential Information so disclosed, in the same form and format so disclosed, together with a description of all persons to whom such Confidential Information was disclosed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. *Access to Information*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. During the Retention Period, each of the parties shall cooperate with and afford, and shall cause their respective affiliates, representatives, subsidiaries, successors and/or assignees, and shall use reasonable efforts to cause joint ventures that are not affiliates (collectively, "***Related Parties***") to cooperate with, and afford to the other party, reasonable access upon reasonable advance written request to all information (other than information created after the effective date of the Spinoff (i) the disclosure of which would have the effect of waiving a legal privilege, or (ii) which is the subject of a confidentiality agreement between such party and a third party which prohibits disclosure to the other party, provided that such party shall use all commercially reasonable efforts to obtain such third party's consent to disclosure of such information) within such party's or any Related Party's possession. Access to the requested information shall be provided so long as it relates to the requesting party's (the "***Requestor***") assets, business and operations, and access is reasonably required by the Requestor as a result of the parties' prior relationship for purposes of auditing, accounting, claims or litigation (except for claims or litigation between the parties), employee benefits, regulatory or tax purposes or fulfilling disclosure or reporting obligations including, without limitation, information reasonably necessary for the preparation of reports required by or filed under the Securities Act of 1933 or the Securities Exchange Act of 1934 with respect to any period entirely or partially before the effective date of the Spinoff or any other reasonable purpose.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Each party agrees to cooperate fully to allow access to each other's employees (i) to the extent that they are reasonably necessary to discuss and explain all requested information with and to the requesting party and (ii) with respect to any claims brought against the other involving the conduct of the Lokahi business before the effective date of the Spinoff.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. *Books and Records*. The Company, Newco and Lokahi shall preserve and keep all of their respective books and records in the possession of such party or its Related Parties, whether in electronic form or otherwise, for no less than the later of (i) the record retention policy of the Company, Newco and Lokahi as in effect as of the date the respective Spinoff is effectuated or (ii) any period as may be required by any promulgated laws, regulations or rulings of any jurisdiction (or of any political subdivision or taxing authority) (the "***Retention Period***"), at such party's sole cost and expense. The Company shall deliver to Lokahi the date the Spinoff is effectuated, any and all original corporate organization books that Company has in its possession relating solely to Lokahi, copies of which the Company may retain at its own expense.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. *Financial and Other Information*. For so long as Company is required to consolidate Lokahi's or Newco's results of operations and financial position (determined in accordance with generally accepted accounting principles consistently applied):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. Lokahi and Newco shall each maintain a system of internal accounting controls in accordance with generally accepted accounting principles and Securities and Exchange Commission (the "***SEC***") and tax related requirements that will provide reasonable assurance that Lokahi's and any subsidiaries' books, records, and accounts fairly reflect all transactions and dispositions of assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Lokahi and Newco shall maintain a fiscal year which commences and ends on the same dates as does Company's fiscal year of each calendar year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. Lokahi shall, as promptly as practicable, deliver to Company copies of all annual and other budgets and financial projections (consistent in terms of format and detail and otherwise with the procedures in effect on the Effective Date) relating to Lokahi or any of its subsidiaries and shall provide Company an opportunity to meet with management of Lokahi to discuss such budgets and projections.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. With reasonable promptness, Lokahi and Newco shall deliver to Company such additional financial and other information and data with respect to Lokahi and its subsidiaries and their business, properties, financial positions, results of operations and prospects as from time to time may be reasonably requested by Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;v. Except with respect to Lokahi's quarterly and annual earnings releases, Lokahi shall deliver to Company as soon as practicable but in no event one business day before issuance, copies of substantially final drafts of all press releases and other statements to be made available by Lokahi or any of its subsidiaries to employees of Lokahi or any of its subsidiaries or to the public concerning material developments in the business, properties, earnings, results of operations, financial condition or prospects of Lokahi or any of its subsidiaries or the relationship between (i) Lokahi or any of its subsidiaries and (ii) Company or any of its affiliates. In addition, within such one day period, before the issuance of any such press release or public statement, Lokahi shall actively consult with Company regarding any changes (other than typographical or other similar minor changes) to such substantially final drafts. Immediately following the issuance, Lokahi shall deliver to Company copies of final drafts of all press releases and other public statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vi. Company and Lokahi shall cooperate fully, and cause their respective accountants to cooperate fully, to the extent requested by the other party in the preparation of the other party's public earnings releases, annual reports on Form 10-K, quarterly reports on Form 10-Q, any current reports on Form 8-K and any other proxy, information and registration statements, reports, notices, prospectuses and any filings made by Company with the SEC, any national securities exchange, any interdealer quotation system or otherwise made publicly available (the "***Public Filings***"). Newco and Lokahi each agree to provide to the Company all information that the Company reasonably requests in connection with any Public Filings or that, in the judgment of either party, is required to be disclosed or incorporated by reference under any law, rule or regulation. Such information shall be provided by such party in a timely manner on the dates requested by the other party (which may be earlier than the dates on which such party otherwise would be required to have such information available) to enable the Company to prepare, print and release all Public Filings on such dates as such party shall determine. Company and Lokahi shall each use its reasonable best efforts to cause their respective accountants to consent to any reference to them as experts Company in any Public Filing required under any law, rule or regulation. If and to the extent requested by either party, the other party shall diligently and promptly review all drafts of such Public Filing and prepare in a diligent and timely fashion any portion of such Public Filing pertaining to that party. Before any printing or public release of any Public Filing, an appropriate executive officer of Company or Lokahi shall, if requested by the other party, certify that the information provided by such party relating to such party, its affiliates or its business in such Public Filing is accurate, true and correct in all material respects. Unless required by law, rule, regulation or generally accepted accounted principles, Lokahi shall not publicly release any financial or other information which significantly conflicts with the information with respect to Lokahi, any of its affiliates or the Lokahi business that is included in any Public Filing without the Company's prior written consent. Before the release or filing, Company and Lokahi shall provide each other with a draft of any portion of a Public Filing containing information relating to the other party and its subsidiaries and shall give such party an opportunity to review such information and comment; provided that the other party shall determine in its sole discretion the final form and content of all Public Filings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vii. Lokahi shall not change its independent certified public accountants without Company's prior consent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;viii. Lokahi and Company shall use reasonable efforts to make available to each other its past and present directors, officers, other employees and agents as witnesses in any legal, administrative or other proceedings in which the other party may become involved and the Company providing information, consultant or witness services under this Agreement will be entitled to reimbursement from the other for reasonable expenses incurred in providing this assistance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ix. Lokahai shall comply with the provisions of this Section 15 as long as its financial statements are required to be included in the Public Filings of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**16. Dismissal of Lawsuit**. Within five (5) business days after the Effective Date, Emerson shall file a stipulation of dismissal without prejudice of the action filed by him in the United States District Court for the Southern District of New York against the Inscobee Parties (the "**Lokahi Action**"). The dismissal shall automatically convert to dismissal with prejudice on the one hundred eightieth (180th) day after the Effective Date, provided there has been no breach by the Inscobee Parties of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**17. Mutual Release of Claims by the Parties**. In consideration of the mutual covenants and promises contained within this Agreement, the parties enter the following releases:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. *Claims to be Released*. "***Claims***" means any and all claims, counterclaims, contribution claims, indemnity claims, demands, allegations, actions, causes of action, judgments, and all other claims of every kind and nature in law or equity, whether arising under state, federal, international or other law, whether such claims are absolute or contingent, direct or indirect, known or unknown, suspected or unsuspected, matured or unmatured, asserted or unasserted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. *Effectiveness of Releases*. The releases contained in the Section 17 shall only be effective upon the payment by Lokahai of the Working Capital Contribution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**18. Acknowledgment of Settlement**. The Inscobee Parties and Lokahi Parties, by signing this Agreement, acknowledge that, except as arising from this Agreement or from a breach of this Agreement, they are giving up forever any right to seek further monetary or other relief from the Company Parties or the Board of Directors, or otherwise specifically excluded in Section 14, for any acts or omissions by the Company Parties up to and including the Effective Date. The Company Parties and Inscobee Parties, by signing this Agreement, acknowledge that, except as arising from this Agreement or from a breach of this Agreement, they are giving up forever any right to seek further monetary or other relief from the Lokahi Parties, as broadly described in Section 14, for any acts or omissions by the Lokahai Parties up to and including the Effective Date. The Company Parties and Lokahai Parties, by signing this Agreement, acknowledge that, except as arising from this Agreement or from a breach of this Agreement, they are giving up forever any right to seek further monetary or other relief from the Inscobee Parties, as broadly described in Section 14, for any acts or omissions by the Inscobee Parties up to and including the Effective Date. The parties acknowledge that this waiver is expressly conditioned upon the full and faithful performance of all obligations and the truthfulness of all disclosures made by the other parties during the settlement process.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**19. Covenant Not To Sue**. The Company Parties, Lokahai Parties and the Inscobee Parties promise not to file any civil complaints or causes of action, whether at law or equity, against one another that assert claims pertaining in any way to or arising out of the Released Matters. For this elimination of doubt, this includes a covenant not to initiate any arbitration relating to the Released Matters. Provided, however, that this Covenant Not to Sue shall not apply to (i) any action or arbitration brought to enforce the terms of this Agreement, or (ii) any claim based on fraud or intentional concealment of material facts that is expressly excluded from the scope of the "Released Matters" under Section 14. Any party successfully asserting such an excluded claim shall be entitled to recover its reasonable attorneys' fees and costs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**20. No Admission of Liability**. The parties acknowledge that the consideration set forth in this Agreement was agreed upon as a compromise and final settlement of Released Matters and that this settlement is not, and may not be construed as, admissions of liability by the such other party and is not to be construed as an admission that such party engaged in any wrongful, tortious, or unlawful activity. The Company Parties and the Board of Directors specifically disclaim and deny any liability to Inscobee Parties and Lokahai Parties, the Lokahai Parties specifically disclaim and deny any liability to the Company Parties, the Board of Directors, and the Inscobee Parties and the Inscobee Parties specifically disclaim and deny any liability to the Company Parties, the Board of Directors, and the Lokahai Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**21. Mutual Non-Disparagement**. The parties agree that they will not, directly or indirectly, disparage, defame, impugn, or otherwise damage or assail the reputation, business, integrity or professionalism of each other's business affairs, practices or policies, standards, or reputation (including but not limited to statements or postings harmful to either party's business interests, reputation or good will) in any form (including but not limited to orally, in writing, on social media, internet, to the media, persons and entities engaged in radio, television or Internet broadcasting, or to persons and entities that gather or report information on trade and business practices or reliability), any other matter related to any claims referred to in this Agreement, or for any other matters related to any past transactions taking place between the parties. Nothing in the Agreement shall, however, be deemed to interfere with each party's obligation to report transactions with appropriate governmental, taxing and/or registering agencies. To the extent the reporting obligations just described require public disclosure of this Agreement, or any terms of this Agreement, the parties agree that they will adhere to the terms of this section and only disclose or comment upon that information necessary to satisfy those reporting obligations required by law, and to the appropriate designated personnel at the applicable governmental, taxing, and/or registering agencies, or organizations requiring and such disclosure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**22. Further Assurances and Cooperation**. The parties agree to execute such additional documents and to take such further actions as may be reasonably requested or necessary in order to give full effect to the consummation of the transaction described in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**23. Miscellaneous**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. *Confidential Information Carve-Out.* No confidentiality, non-use or non-disclosure obligation applies to, any information relating to Lokahai's business, assets, employees, operations or know-how, and each Lokahi Party may use and disclose such information without restriction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. *Voluntary Execution*. Each party acknowledges and represents that it is executing this Agreement voluntarily, free from any undue influence, coercion, duress, or menace of any kind.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. *No Reliance*. Each party agrees that he, it, or they have not relied on any representations, statements, assertions, assumptions, or other statements that are not included within this Agreement. Each party further agrees that that there are no statements of fact outside this Agreement that such party is relying on in any way.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. *Assigns*. This Agreement will inure to the benefit of and be binding upon the heirs, executors, administrators, successors, assigns, and designees of the parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. *Notice*. All notices, consents, requests, approvals and other communications provide for in this Agreement, shall be in writing and shall be deemed validly duly given when sent by confirmed fax, upon personal delivery or on the third Business Day after being sent by registered or certified U.S. mail (postage prepaid, return receipt requested) to the parties at the fax number or address set forth below or at such other fax number or address as a party may designate to the other parties:

If to Inscobee, to:

suite 613, Namsung Plaza, 47, Digital-ro 9-gil, Geumcheon-gu, Seoul, Republic of Korea

Attn: Jerry Hyukjae Lee

E-mail: jerrylee@inscobee.com

If to Apimeds Korea, to:

suite 1303, Namsung Plaza, 47, Digital-ro 9-gil, Geumcheon-gu, Seoul, Republic of Korea

Attn: Insoo You

E-mail: apimeds@apimeds.co.kr

If to Company, to:

60 Paya Lebar Road.

#04-23

Singapore 409051

Attn: Vin Menon

E-mail: vin@mindwavedao.com

If to Lokahi, to:

Lokahi Therapeutics, Inc.

3366 N. Torrey Pines Court, #140

La Jolla, CA 92037

Kim Life, General Counsel

kim@lokahithera.com

If to Erik Emerson, to:

Lokahi Therapeutics, Inc.

3366 N. Torrey Pines Court, #140

La Jolla, CA 92037

Erik Emerson, CEO

erik@lokahithera.com

If to MindWave, to:

TechyTrade Innovations Pte Ltd

60 Paya Lebar Road.

#04-23

Singapore 409051

Attn: Vin Menon

E-mail: vin@mindwavedao.com

with a copy (which shall not constitute notice) to:

Duane Morris LLP

901 New York Avenue N.W., Suite 700 East

Washington, D.C. 20001-4795

Attn: Andrew M. Tucker

E-mail: atucker@duanemorris.com

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. *No Tax Representations*. The parties shall be responsible for their own tax liability occasioned by this Agreement. Neither party shall be liable to the other party for any federal, national, state, or local taxes that any taxing authority may impose on the other party as a result of this Agreement, provided, however, that to the extent any tax position taken by one party may affect a tax position taken by the other party, the parties shall cooperate in good faith to coordinate consistent tax positions. No party is relying on any representation or warranty outside this Agreement related or pertaining to income taxes, or any other subject.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. *Specific Performance*. Each party acknowledges that the rights of each party to this Agreement to consummate the contemplated transactions are unique, recognizes, and affirms that in the event of a breach of this Agreement by any party, money damages may be inadequate and the non-breaching parties may have not adequate remedy at law, and agree that irreparable damage would occur if any of the provisions of this Agreement were not performed by an applicable party in accordance with their specific terms or were otherwise breached. Accordingly, each party will be entitled to seek an injunction or restraining order to prevent breaches of this Agreement and to seek to enforce specifically the terms and provisions, without the requirement to post any bond or other security or to prove that money damages would be inadequate, this being in addition to any other right or remedy to which such party may be entitled under this Agreement, at law or in equity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;h. *WAIVER OF JURY TRIAL*. EACH PARTY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE CONTEMPLATED TRANSACTIONS. EACH PARTY (A) CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, SEEK TO ENFORCE THAT FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. *Fees and Expenses*. The parties agree to bear their own attorneys' fees, costs, and expenses incurred in connection with any dispute between the Company Parties, the Lokahai Parties and the Inscobee Parties, and the matters resolved through this Agreement, including all associated fees and costs. If any of the parties are required to file suit or to otherwise enlist the aid of legal counsel to compel performance or enforce the terms and conditions of this Agreement, the party that prevails in the litigation, as determined by a court of competent jurisdiction, shall be entitled to recover their reasonable attorneys' fees and costs incurred in such action.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;j. *Amendment*. This Agreement may be amended, supplemented or modified only by execution of a written instrument signed by the parties to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;k. *Severability*. In case any provision in this Agreement will be held invalid, illegal or unenforceable in a jurisdiction, such provision will be modified or deleted, as to the jurisdiction involved, only to the extent necessary to render the same valid, legal and enforceable, and the validity, legality and enforceability of the remaining provisions will not in any way be affected or impaired nor will the validity, legality or enforceability of such provision be affected in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties will substitute for any invalid, illegal or unenforceable provision a suitable and equitable provision that carries out, so far as may be valid, legal and enforceable, the intent and purpose of such invalid, illegal or unenforceable provision.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;l. *Counterparts*. This Agreement may be executed and delivered (including by facsimile or other electronic transmission) in one or more counterparts, and by the different parties in separate counterparts, each of which when executed will be deemed to be an original but all of which taken together will constitute one and the same agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;m. *Entire Agreement*. This Agreement and the documents or instruments referred to in this Agreement, including any exhibits and schedules attached, which exhibits and schedules are incorporated by reference, embody the entire agreement and understanding of the parties in respect of the subject matter. There are no restrictions, promises, representations, warranties, covenants or undertakings, other than those expressly set forth or referred to or the documents or instruments, which collectively supersede all prior agreements and the understandings among the parties with respect to the subject matter contained in this Agreement.

[*Signature page follows*]

The parties have executed this Agreement as of the Effective Date.

---

| | |
|:---|:---|
| **Apimeds Pharmaceuticals US, Inc.**, | **Apimeds Pharmaceuticals US, Inc.**, |
| a Delaware corporation | a Delaware corporation |
| By: |  |
| Name: | Dr. Vin Menon |
| Title: | Chief Executive Officer |
| **MindWave Innovations Inc**, a | **MindWave Innovations Inc**, a |
| Delaware corporation | Delaware corporation |
| By: |  |
| Name: | Dr. Vin Menon |
| Title: | Chief Executive Officer |
| **Lokahi Therapeutics, Inc.**, a | **Lokahi Therapeutics, Inc.**, a |
| Nevada corporation | Nevada corporation |
| By: |  |
| Name: | Erik Emerson |
| Title: | Chief Executive Officer |
| **Erik Emerson, Individually** | **Erik Emerson, Individually** |
| By: |  |
| **Erik Emerson, in his capacity as Bio Representative** | **Erik Emerson, in his capacity as Bio Representative** |
| By: |  |
| Title: | Bio Representative |
| **Inscobee Inc.**, a South Korean | **Inscobee Inc.**, a South Korean |
| corporation | corporation |
| By: |  |
| Name: | Insoo You |
| Title: | Chief Executive Officer |
| **Apimeds Inc.**, a South Korean | **Apimeds Inc.**, a South Korean |
| corporation | corporation |
| By: |  |
| Name: | Insoo You |
| Title: | Chief Executive Officer |

---

**EXHIBIT A**

**<u>Irrevocable Proxy</u>**

**FORM OF IRREVOCABLE PROXY**

**APIMEDS PHARMACEUTICALS US, INC.**

**THIS IRREVOCABLE PROXY IS BEING EXECUTED BY THE UNDERSIGNED STOCKHOLDER.**

The undersigned stockholder (the "***Stockholder***") of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the "***Company***"), hereby appoints Dr. Vin Menon and Captain Sandeep Singh Yadav, and each of team, acting individually, as the true and lawful proxy and attorney-in-fact of the undersigned, with full power of substitution, to vote all the shares of common stock in the Company that the undersigned is entitled to vote at any meeting of stockholders of the Company, or any adjournment or postponement, and in any action by written consent.

**THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS DIRECTED BELOW. IF NO DIRECTION IS GIVEN, THIS PROXY WILL BE VOTED "FOR" ALL PROPOSALS.**

**PROPOSALS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.** **The Preferred Stock Conversion and Issuance**: the issuance of the Company ' s
shares of common stock, par value $0.01 per share (the "  ***Common Stock*** ")
upon the conversion of the Series A Convertible Preferred Stock, par value $0.01 per share of the Company.

☒ FOR ☐ AGAINST ☐ ABSTAIN

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.** **The Note Approval and Issuance**: the issuance of the Company Common Stock upon the conversion of
the convertible notes issued by the Company pursuant to that certain Securities Purchase Agreement, entered into by the Company and certain
institutional investors on December 1, 2025, and amended by that certain Amendment No. 1 to Securities Purchase Agreement on December
8, 2025.

☒ FOR ☐ AGAINST ☐ ABSTAIN

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.** **The Reverse Stock Split**: a 1-for-10 reverse stock split (the "  ***Reverse Stock Split***") of the Company ' s Common Stock, a change in the par value per share
of the Company ' s Common Stock from $0.01 to $0.001 (the "  ***Change in Par Value*** "), and a corresponding amendment to the Company ' s Amended and Restated
Certificate of Incorporation to (i) authorize the board of directors of the Company to effect the Reverse Stock Split, and (ii) the Change
in Par Value.

☒ FOR ☐ AGAINST ☐ ABSTAIN

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.** **The 2024 Plan Share Increase**: an amended to the Apimeds Pharmaceuticals US, Inc. 2024 Equity Incentive
Plan (the "  ***2024 Plan***") to increase the number of shares of Common Stock
issuable under the 2024 Plan to 2,096,679.

☒ FOR ☐ AGAINST ☐ ABSTAIN

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.** **The 2025 Equity Plan**: the approval and adoption of the Apimeds Pharmaceuticals US, Inc. 2025 Equity
Incentive Plan.

☒ FOR ☐ AGAINST ☐ ABSTAIN

**COVENANTS OF THE STOCKHOLDER**

The undersigned Stockholder hereby agrees:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **No Impeding Actions**. The Stockholder shall not vote, consent, or take any other action with respect
to the Common Stock owned beneficially or of record by the Stockholder, nor grant any proxy or enter into any agreement, that would reasonably
be expected to delay, impede, interefere with, or adversely affect (i) the Agreement and Plan of Merger entered into on December 1, 2025,
by the Company, MindWave Innovations Inc, a Delaware corporation ("  ***MindWave*** "),
and other parties signatory thereto, or any of the transactions contemplated thereby, or (ii) the approval or consummation of any of the
proposals set forth in this proxy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **No Board Changes**. The Stockholder shall not vote, consent, or take any other action with respet
to the Common Stock owned beneficially or of record by the Stockholder, nor grant any proxy or enter into any agreement, to remove, replace,
or otherwise alter the composition of the current members of the Company ' s board of directors.

**DISCRETIONARY AUTHORITY**

The proxy holders are authorized to vote in their discretion upon such other business as may properly come before the meeting or any adjournment or postponement, subject to the covenants set forth above.

**IRREVOCABILITY**

This proxy will be given in consideration of the agreements and covenants of the Company in connection with the transactions contemplated by that certain Confidential Settlement and Mutual Released (the "***Settlement Agreement***") entered into on April [____], 2026 by (i) the Company, (ii) MindWave, (iii) Erik Emerson individually and as Bio Business Representative (iv) Lokahi Therapeutics, Inc., a Nevada corporation, (v) Inscobee Inc., a South Korean Corporation, and (vi) Apimeds Inc., a South Korean corporation, and, as such, is coupled with an interest and shall be irrevocable.

**EXECUTION**

The undersigned Stockholder has executed this proxy as of the date written below.

---

| |
|:---|
| Name of Stockholder |
| Signature |
| Title (if applicable) |
| Number of Shares Held |
| Date |

---

## Exhibit 10.2

**Exhibit 10.2**

**SIDE LETTER AGREEMENT**

**MERGER UNWIND CONDITIONS**

(This "Side Letter" is incorporated into and forms part of the Confidential Settlement and Mutual Release Agreement dated April 24, 2026)

This Side Letter Agreement (this **"Side Letter"**) is entered into as of April 24, 2026 (the **"Effective Date"**), by and among the following parties:

**Apimeds Pharmaceuticals US, Inc.**, a Delaware corporation (the **"Company"**);

**MindWave Innovations Inc**, a Delaware corporation and wholly owned subsidiary of the Company (**"MindWave"**);

**Erik Emerson**, individually and as Bio Business Representative under the Merger Agreement (**"Emerson"**);

**Lokahi Therapeutics, Inc.**, a Nevada corporation (**"Lokahi"**);

**Inscobee Inc.**, a South Korean corporation (**"Inscobee"**); and

**Apimeds Inc.**, a South Korean corporation and wholly owned subsidiary of Inscobee (**"Apimeds Korea"**, together with Inscobee, the **"Inscobee Parties"**).

**RECITALS**

A. The parties have entered into that certain Confidential Settlement and Mutual Release Agreement dated as of the Effective Date (the **"Settlement Agreement"**), which governs the resolution of certain disputes arising out of the Agreement and Plan of Merger dated December 1, 2025 (the **"Merger Agreement"**).

B. The parties wish to supplement the Settlement Agreement by setting forth certain additional conditions relating to the potential unwind of the Merger Agreement, as more fully described herein.

C. This Side Letter is intended to be legally binding and is incorporated by reference into the Settlement Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Settlement Agreement.

**AGREEMENT**

In consideration of the mutual covenants and agreements set forth herein and in the Settlement Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

**1. Merger Unwind Conditions.**

Notwithstanding anything to the contrary in the Settlement Agreement or the Merger Agreement, the parties agree that the transactions contemplated by the Merger Agreement shall be subject to unwind, or such other remedy as mutually agreed by the parties in writing, upon the occurrence of either of the following events (each, a **"Triggering Event"**):

● the Company fails to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission on or before April 30, 2026; or

● the consolidated audit report included in such Form 10-K receives a qualified opinion from the Company's PCAOB-registered independent auditors for any reason.

**2. Meet and Confer Obligation.**

In the event either Triggering Event set forth in Section 1 is triggered, the parties shall meet and confer within five (5) business days of such triggering event to negotiate in good faith the appropriate remedy. Such remedy may include, without limitation:

● unwind of the Merger Agreement and reversal of the transactions contemplated thereby;

● adjustment of the consideration exchanged pursuant to the Merger Agreement; or

● such other relief, restructuring, or alternative arrangement as the parties may agree in writing.

No party shall be bound by any particular remedy unless and until such remedy is reduced to a written agreement signed by all parties.

**3. Good Faith Negotiations.**

During any meet-and-confer period triggered under Section 2, each party agrees to negotiate in good faith and to provide the other parties with reasonable access to information necessary to evaluate the appropriate remedy. No party shall take any unilateral action to unwind, rescind, or otherwise reverse the Merger Agreement or the transactions contemplated thereby without the prior written consent of all other parties.

**4. Reciprocal Delegation of Authority and Irrevocable Proxy.**

In the event a Triggering Event occurs due to the act or omission of any party (the "Defaulting Party"), such Defaulting Party's voting rights and all decision-making authority pertaining to the resolution of the Triggering Event, the determination of remedies under Section 2, or any restructuring of the Merger Agreement shall be automatically and irrevocably delegated to the other party or parties who are not responsible for such Triggering Event (the "Non-Defaulting Parties").

Notwithstanding the foregoing, as Lokahi Therapeutics, Inc. ("Lokahi") is not a shareholder of the Company (Apimeds Pharmaceuticals US, Inc.), Lokahi shall not be entitled to receive, hold, or exercise any delegated voting rights under this Section under any circumstances, and Lokahi is hereby expressly excluded from the scope of such delegation.

The Defaulting Party hereby grants to the Non-Defaulting Parties (excluding Lokahi) an irrevocable proxy, coupled with an interest, to vote and exercise all rights and powers of the Defaulting Party with respect to the subject matter of this Side Letter. This delegation shall remain in effect until the Triggering Event is fully resolved or a written agreement on the remedy is signed by the Non-Defaulting Parties. The Defaulting Party shall provide all necessary cooperation and information.

**5. No Waiver of Rights.**

This Side Letter does not constitute a waiver of any party's rights under the Settlement Agreement, the Merger Agreement, or applicable law, except as expressly set forth herein. The rights and remedies provided in this Side Letter are cumulative and in addition to, and not in lieu of, any other rights or remedies available to the parties at law, in equity, or under the Settlement Agreement.

**6. Incorporation into Settlement Agreement.**

This Side Letter is incorporated into and made a part of the Settlement Agreement. In the event of any conflict between the terms of this Side Letter and the Settlement Agreement, the terms of this Side Letter shall control with respect to the subject matter hereof.

**7. Governing Law; Dispute Resolution.**

This Side Letter shall be governed by and construed in accordance with the laws applicable to the Settlement Agreement, without regard to conflict-of-law principles. Any disputes arising under this Side Letter shall be resolved in accordance with the dispute resolution provisions of the Settlement Agreement, including the jury trial waiver set forth therein.

**8. Miscellaneous.**

**(a) Entire Agreement.** This Side Letter, together with the Settlement Agreement and the documents referred to therein, constitutes the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior discussions, negotiations, and understandings with respect thereto.

**(b) Amendment.** This Side Letter may not be amended, supplemented, or modified except by a written instrument signed by all parties hereto.

**(c) Counterparts.** This Side Letter may be executed in one or more counterparts, including by electronic or facsimile signature, each of which shall be deemed an original and all of which together shall constitute one and the same instrument.

**(d) Severability.** If any provision of this Side Letter is held invalid, illegal, or unenforceable, the remaining provisions shall remain in full force and effect.

**(e) No Admission of Liability.** Nothing in this Side Letter shall constitute an admission of liability or wrongdoing by any party.

**(f) Voluntary Execution.** Each party represents and warrants that it is executing this Side Letter voluntarily, free from any undue influence, coercion, or duress.

**IN WITNESS WHEREOF**, the parties have executed this Side Letter Agreement as of the Effective Date.

---

| | |
|:---|:---|
| *Apimeds Pharmaceuticals US, Inc., a Delaware corporation* | *Apimeds Pharmaceuticals US, Inc., a Delaware corporation* |
| By: |  |
| Name: | Dr. Vin Menon |
| Title: | Chief Executive Officer |
| Date: | April 24, 2026 |
| *MindWave Innovations Inc, a Delaware corporation* | *MindWave Innovations Inc, a Delaware corporation* |
| By: |  |
| Name: | Dr. Vin Menon |
| Title: | Chief Executive Officer |
| Date: | April 24, 2026 |
| *Lokahi Therapeutics, Inc., a Nevada corporation* | *Lokahi Therapeutics, Inc., a Nevada corporation* |
| By: |  |
| Name: | Erik Emerson |
| Title: | Chief Executive Officer |
| Date: | April 24, 2026 |
| *Erik Emerson, Individually* | *Erik Emerson, Individually* |
| By: |  |
| *Erik Emerson, in his capacity as Bio Representative* | *Erik Emerson, in his capacity as Bio Representative* |
| By: |  |
| Title: | Bio Representative |
| *Inscobee Inc., a South Korean corporation* | *Inscobee Inc., a South Korean corporation* |
| By: |  |
| Name: | Insoo You |
| Title: | Chief Executive Officer |
| Date: | April 24, 2026 |
| *Apimeds Inc., a South Korean corporation* | *Apimeds Inc., a South Korean corporation* |
| By: |  |
| Name: | Insoo You |
| Title: | Chief Executive Officer |
| Date: | April 24, 2026 |

---

## Exhibit 10.3

**Exhibit 10.3**

**<u>FORBEARANCE AGREEMENT</u>**

This Forbearance Agreement ("**Agreement**") is made and entered into this 30<sup>th</sup> day of April, 2026, by and between, ALTO OPPORTUNITY MASTER FUND, SPC – SEGREGATED MASTER PORTFOLIO B ("**Investor**") and APIMEDS PHARMACEUTICALS US, INC., a Delaware corporation (the "**Company**") (collectively, the "**Parties**").

WHEREAS, the Parties refer herein to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) that certain Securities Purchase Agreement, dated December 1, 2025, by and among the Company and the investors party thereto (including Investor) (as amended, restated or otherwise modified from time to time prior to the date hereof, the "**Securities Purchase Agreement**"), pursuant to which, among other things, the Company issued to Investor that certain senior convertible note, dated as of December 8, 2025, in the aggregate original principal amount of $10,900,000 (as amended, restated or otherwise modified from time to time prior to the date hereof, the "**Existing Note**"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) capitalized terms not defined herein shall have the meaning as set forth in the Securities Purchase Agreement.

WHEREAS, an Event of Default (as defined in the Existing Note) has occurred pursuant to Section 4(a)(i) of the Existing Note, the Company has failed to file a Registration Statement (as defined in the Registration Rights Agreement) by the fifth (5<sup>th</sup>) day after the Filing Deadline (as defined in the Registration Rights Agreement), which default remains uncured as of the date hereof (the "**Filing Deadline Default**");

WHEREAS, an Event of Default has occurred pursuant to Section 4(a)(i) of the Existing Note, the Company has failed to cause the Registration Statement to be declared effective by the SEC by the fifth (5<sup>th</sup>) day after the Effectiveness Deadline (as defined in the Registration Rights Agreement), which default remains uncured as of the date hereof (the "**Effectiveness Deadline Default**");

WHEREAS, an Event of Default has occurred pursuant to Section 4(a)(xiv) of the Existing Note, the Company has failed to obtain the Stockholder Approval by the Stockholder Approval Deadline, which default remains uncured as of the date hereof (the "**Stockholder Approval Default**");

WHEREAS, prior to the Initial Closing, certain stockholders of the Company (each, a "**Majority Stockholder**"), notified the Company that the Stockholder Consent and certain Voting Agreements had been withdrawn (the "**Majority Shareholder Dispute**") and the Company delivered such Stockholder Consent and Voting Agreements to the Holder pursuant to Section 7 of the Securities Purchase Agreement without notifying the Holder of the Majority Stockholder Dispute;

WHEREAS, an Event of Default has occurred pursuant to Section 4(a)(xiv) of the Existing Note, (i) the existence of the Majority Stockholder Dispute and (ii) the Company's failure to notify Investor of the Majority Stockholder Dispute, in each case, breached certain representations, warranties and covenants under the Transaction Documents, which default remains uncured as of the date hereof (the "**Breach of Representations and Warranties Default**");

WHEREAS, an Event of Default has occurred pursuant to Section 4(a)(xvii) of the Existing Note, the Majority Stockholder Dispute has caused a Material Adverse Effect to occur, which default remains uncured as of the date hereof (the "**Material Adverse Effect Default**", and collectively with the Filing Deadline Default, the Effectiveness Failure Default, the Stockholder Approval Default and the Breach of Representations and Warranties Default, the "**Existing Defaults**");

WHEREAS, the Company has requested that the Investor agree to forbear from exercising any of its rights or remedies under the Existing Note during the period commencing on the date hereof through and including June 30, 2026 (or such later date as Investor may elect in its sole discretion) (the "**Forbearance Expiration Date**"); and

WHEREAS, in connection with, and as additional consideration for such forbearance, the Company has agreed to: (i) deliver to Investor a settlement agreement, in form and substance acceptable to Investor, by and among the Company and the Majority Stockholders (the "**Settlement Agreement**"), pursuant to which, among other things, each Majority Stockholder agrees to comply with its obligations under the Stockholder Consent and the Voting Agreements, duly executed by the Company and the Majority Stockholders on or prior to April 29, 2026; (ii) execute and deliver to Investor the Amendment No. 1 to Senior Secured Convertible Note, in the form attached hereto as **<u>Exhibit A</u>** (the "**Amendment**"), on or prior to April 30, 2026; (iii) file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 with the SEC on or prior to April 30, 2026; (iv) file the initial Registration Statement with the SEC on or prior to May 10, 2026, and that such Registration Statement shall be declared effective by the SEC on or prior to June 30, 2026; (v) cure all deficiencies, and regain compliance, with the New York Stock Exchange's (the "**NYSE**") continued listing requirements, including, without limitation, (x) obtain NYSE approval of the Change of Control, the Preferred Stock Conversion, the Note Approval and the NYSE Listing Application (in each case, as defined in the Settlement Agreement), (y) effect the reverse stock split of the Common Stock at a ratio of 1-for-10, and (z) resume trading of the Common Stock on the Principal Market, in each case on or prior to June 30, 2026 (or such later date as Investor may elect in its sole discretion); and (vi) cause the members of the Company's Board of Directors to be appointed in accordance with Section 10(a) of the Settlement Agreement on or prior to June 30, 2026 (or such later date as Investor may elect in its sole discretion), (collectively, the "**Forbearance Conditions**").

NOW, THEREFORE, in consideration of the promises, mutual covenants, understandings and agreements contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are acknowledged by all parties, the parties do hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **<u>Forbearance</u>**. Effective upon execution of this Agreement and the Amendment until the Forbearance Expiration Date (the "**Forbearance Period**"), Investor agrees not to exercise any of its rights or remedies with respect to the Existing Defaults that exist as of the date of this Agreement (the "**Forbearance**"). The Forbearance Period shall terminate upon the earliest to occur of: (x) the occurrence, or discovery by Investor, of any Event of Default (as defined in the Existing Note) (other than the Existing Defaults), (y) any breach of any term or condition of this Agreement or the Settlement Agreement, and (z) the Company fails to timely satisfy any of the Forbearance Conditions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **<u>Limited Waiver</u>**. Provided that the Company is not in breach of its obligations under this Agreement, effective upon the timely satisfaction of all of the Forbearance Conditions, Investor hereby waives the Existing Defaults (the "**Limited Waiver**"). The Limited Waiver set forth herein constitutes a one-time waiver and is limited to the matters expressly waived herein and should not be construed as an indication that Investor would be willing to agree to any future modifications to, consent of, or waiver of any of the terms of any other agreement, instrument or security or any modifications to, consents of, or waiver of any other default that may exist or occur thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **<u>Rights; Effective Date</u>**. Notwithstanding anything herein to the contrary, nothing herein shall be deemed to limit the rights of Investor with respect to any amounts outstanding under the Existing Note at any time of determination with respect to any Event of Default other than the Existing Defaults and, solely during the Forbearance Period, the Forbearance, or with respect to any right, remedy, election among remedies, or defense not expressly described in the Forbearance, and all such rights, remedies, elections among remedies, and defenses of Investor are hereby reserved. This Agreement shall be effective upon the due execution of this Agreement by the Parties (the "**Effective Date**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **<u>Investor's Representations and Warranties</u>**. Investor represents and warrants as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. It is not under any contractual or other restriction or other obligation which is inconsistent with this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. It has not assigned to any Person any right, claim or cause of action encompassed or arising from matters set forth in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. It has had a full and fair opportunity to make inquiries about the terms and conditions of this Agreement, to discuss the same and all related matters with its own independent counsel, accountant and tax advisers; and this Agreement has been executed and delivered by it of its own free will and without promises, threats or the exertion of any duress.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. This Agreement has been duly executed by Investor and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of Investor enforceable against Investor in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors' rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. Investor is an "accredited investor," as such term is defined in Rule 501 of Regulation D promulgated under 1933 Act, and Investor is able to bear the economic risk of an investment in securities of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. **<u>Company's Representations and Warrants.</u>** Company represents and warrants as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. It is not under any contractual or other restriction or other obligation which is inconsistent with this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. It has not assigned to any Person any right, claim or cause of action encompassed or arising from matters set forth in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. The execution and delivery of this Agreement and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or the Company's stockholders in connection therewith. This Agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligations of the Company, enforceable against the Company in accordance with its terms except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors' rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **<u>Release</u>**. In further consideration of Investor's execution of this Agreement, the Company, on behalf of itself and its successors, assigns, parents, Subsidiaries, Affiliates, officers, directors, employees, agents and attorneys, hereby forever, fully, unconditionally and irrevocably waives and releases Waqas Khatri, Ayrton Capital LLC, Investor and each of their respective successors, assigns, parents, subsidiaries, affiliates, officers, directors, employees, attorneys and agents (collectively, the "**Ayrton Releasees**") from any and all claims, liabilities, obligations, debts, causes of action (whether at law or in equity or otherwise), defenses, counterclaims, setoffs, of any kind, whether known or unknown, whether liquidated or unliquidated, matured or unmatured, fixed or contingent, directly or indirectly arising out of, connected with, resulting from or related to any act or omission by any Ayrton Releasee, on or prior to the date hereof (or, to the extent that Investor waives any Existing Defaults pursuant to this Agreement through a later date, such later date), with respect to the Transaction Documents, the transactions contemplated thereby or any enforcement or attempted enforcement of the Transaction Documents by any Ayrton Releasee and any transactions in the Common Stock effected by any Ayrton Releasee (collectively, the "**Ayrton Claims**"). The Company further agrees that it shall not commence, institute, or prosecute any lawsuit, action or other proceeding, whether judicial, administrative or otherwise, to prosecute, collect or enforce any Ayrton Claim. Notwithstanding anything to the contrary in any of the Transaction Documents, the Company will promptly reimburse Investor for all costs, including attorney's fees, paid or incurred, in defending against any Ayrton Claims.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. **<u>Binding</u>**. This Agreement shall inure to the benefit of the parties and shall be binding upon each of the parties and their assigns, successors, heirs, and representatives.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. **<u>Authority</u>**. Each of the Parties represents and warrants that it has the authority to enter into this Agreement, that the person(s) signing this Agreement on its behalf is authorized to do so and that it has not assigned or otherwise transferred any interest in any claim which is the subject of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. **<u>No Recitals</u>**. Each of the Parties agrees and understands that all of the terms of this Agreement are contractual and not merely recitals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. **<u>No Duress</u>**. Each of the Parties to this Agreement was represented by counsel and this Agreement was negotiated at arm's length and should not be read against any party. Each of the Parties and their respective counsel acknowledge that they have carefully read and fully understand the provisions of this Agreement, that they have been given a reasonable period of time to consider the terms of this Agreement, and that they enter into this Agreement knowingly and voluntarily and not as a result of any pressure, coercion, or duress and thus no party shall attempt to invoke the rule of construction to the effect that ambiguities, if any, are to be resolved against the drafting party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. **<u>Severability</u>**. If any of the provisions of this Agreement is held by a court of competent jurisdiction to be invalid, void, or otherwise unenforceable, the remaining provisions shall nevertheless continue in full force and effect without being impaired or invalidated in any way.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. **<u>Choice of Law and Venue</u>**. This Agreement will be governed as to validity, interpretation, construction, effect and in all other respects by the internal laws of the State of New York, without giving effect to any provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. The Company and Investor each (i) agree that any legal suit, action or proceeding arising out of or relating to this Agreement shall be instituted exclusively in the New York State Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, (ii) waives any objection to the venue of any such suit, action or proceeding, and the right to assert that such forum is an inconvenient forum, and (iii) irrevocably consents to the jurisdiction of the New York State Supreme Court, County of New York, and the United States District Court for the Southern District of New York in any such suit, action or proceeding. Each of the Company and Investor further agrees to accept and acknowledge service of any and all process that may be served in any such suit, action or proceeding in the New York State Supreme Court, County of New York, or in the United States District Court for the Southern District of New York and agree that service of process upon it mailed by certified mail to its address set forth for notices herein shall be deemed in every respect effective service of process in any such suit, action or proceeding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. **<u>Entire, Final and Binding Agreement</u>**. Each of the Parties acknowledges and agrees that this Agreement is the final and binding Agreement between them concerning the matters released. This writing contains the entire Agreement of the Parties and, in entering into this Agreement, each of the Parties acknowledges that it has not relied on any promise, agreement, representation or statement, whether oral or written, that is not expressly set forth in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. **<u>Amendments or Waivers</u>**. No change to or modification of this Agreement shall be valid or binding unless it is in writing and signed by the Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. **<u>Counterparts</u>**. This Agreement may be signed in counterparts and, if so signed, this Agreement shall have the same force and effect as if signed at the same time. A facsimile, docusign or PDF signature shall be deemed to be an original signature for all purposes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16. **<u>Notices</u>**. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (i) the date of transmission, if such notice or communication is delivered via e-mail at the email addresses set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a business day, (ii) the next business day after the date of e-mail, if such notice or communication is delivered via email at the email address set forth on the signature pages attached hereto on a day that is not a business day or later than 5:30 p.m. (New York City time) on any business day, (iii) the second (2nd) business day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (iv) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17. **<u>Amendment to Securities Purchase Agreement; Ratification</u>**. Effective as of the Effective Date, the defined term "Transaction Documents" in the Securities Purchase Agreement is hereby amended to include this Agreement. Except as otherwise expressly provided herein, each of the Transaction Documents is, and shall continue to be, in full force and effect and is hereby ratified and confirmed in all respects. Effective as of the date hereof, the parties hereby further agree that the Securities Purchase Agreement is hereby amended as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Exhibit A-2 of the Securities Purchase Agreement is hereby amended and restated in the form of **<u>Exhibit B</u>** attached hereto; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. The definition of "Additional Mandatory Closing Eligibility Condition" in Section 1(ii)(1) of the Securities Purchase Agreement is hereby amended to additionally require the written consent of each Buyer, which may be withheld at the sole option of each such Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18. **<u>8-K Filing</u>**. The Company shall, on or before 9:30 a.m., New York City time, on May 1, 2026, issue a Current Report on Form 8-K attaching this letter agreement as an exhibit thereto (including all attachments, the "**8-K Filing**") disclosing all material terms of the transactions contemplated hereby. From and after the filing of the 8-K Filing, Investor shall not be in possession of any material, nonpublic information received from the Company or any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, that is not disclosed in the 8-K Filing. The Company shall not, and shall cause its officers, directors, employees, affiliates and agents, not to, provide Investor with any material, nonpublic information regarding the Company from and after the filing of the 8-K Filing without the express written consent of Investor. To the extent that the Company delivers any material, non-public information to Investor without Investor's express prior written consent, the Company hereby covenants and agrees that Investor shall not have any duty of confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agent with respect to, or a duty to the to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agent or not to trade on the basis of, such material, non-public information. The Company shall not disclose the name of Investor in any filing, announcement, release or otherwise, unless such disclosure is required by law or regulation. In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the older or any of its affiliates, on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that Investor will rely on the foregoing representations in effecting transactions in securities of the Company.

[The remainder of the page is intentionally left blank.]

**IN WITNESS WHEREOF**, expressly intending to be legally bound, the Parties through their duly authorized agents, have executed this Agreement as of the date set forth above, effective as of the Effective Date.

---

| | |
|:---|:---|
| **APIMEDS PHARMACEUTICALS US, INC.** | **ALTO OPPORTUNITY MASTER FUND, SPC – SEGREGATED MASTER PORTFOLIO B** |

---

---

| | | | |
|:---|:---|:---|:---|
| By: |  | By: |  |
| Name: | Dr. Vin Menon | Name: | Waqas Khatri |
| Title: | Chief Executive Officer | Title: | Director |
| Address: |  | Address: |  |

---

E-mail: vin@mindwavedao.com Email: wk@ayrtonllc.com

**<u>EXHIBIT A</u>**

**(Insert form of Amendment)**

**<u>EXHIBIT B</u>**

**(Insert Exhibit A-2 of the Securities Purchase Agreement)**